and that they relied too much on studies unrelated to how people actually use ranitidine, such as NDMA exposure from food or ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Zantac was originated by GSK and launched by ... there have been 15 peer-reviewed epidemiological studies on the effects of ranitidine use on humans which reflect the scientific consensus that ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Zantac’s manufacturers were on a roll ... nationwide marketing campaign to convince doctors—and patients, for the first time ever—to use ranitidine because of its purportedly superior safety profile, ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The ...